|
Corporate Social Responsibility
News
11.19.2007 - 09:00am ET
|
CSR News from:
|
|
|
News Categories: |
| | |
Merck Company Foundation Expands Network of Immunization Training Centers in Africa
(CSRwire) WHITEHOUSE STATION, N.J. - November 19, 2007 - The Merck Company Foundation
announced today a $2.8 million commitment to establish two new immunization
training centers in Uganda and Zambia and to expand the Foundation's
support of two existing centers in Kenya and Mali as part of the Merck
Vaccine Network - Africa. The Merck Vaccine Network - Africa, a
multi-year philanthropic initiative, supports academic partnerships in the
development of sustainable immunization training centers to increase the
number of skilled health professionals in Africa. Today's announcement,
when added to the Foundation's initial commitment of $1.6 million, more
than doubles the Foundation's total commitment to $4.4 million in funding
for these four centers.
"In sub-Saharan Africa, more than 9.6 million children each year do not
receive the most basic vaccines," said Margaret G. McGlynn, president,
Merck Vaccines and Infectious Disease. "Through training of local health
professionals, our investment in the Merck Vaccine Network - Africa will
help to remove barriers that stand between African children and the
vaccines they need. This initiative also reflects Merck's strong support
of the GAVI Alliance and of the U.N. Millennium Development Goals,
including reducing by two thirds the mortality rate among children under
five by 2015."
The Merck Company Foundation, the philanthropic arm of the global
research-based pharmaceutical company Merck & Co., Inc., launched the
Merck Vaccine Network – Africa in 2003 as part of the Company's
commitment to the GAVI Alliance, a public-private partnership that works
to extend the reach and quality of immunization coverage in least
developed countries.
The new funding from The Merck Company Foundation will provide for the
development of two additional centers in:
Uganda, a collaboration between The Task Force for Child Survival and
Development, Emory University (Decatur, Georgia, U.S.A.) and Makerere
University School of Public Health (Kampala, Uganda); and
Zambia, a collaboration between Brighton and Sussex University
Hospitals NHS Trust (Brighton, England, U.K.) and the University of Zambia
School of Medicine (Lusaka, Zambia).
Each new center will receive an annually renewable grant of $200,000, up
to a maximum of $800,000 over four years.
The Merck Company Foundation selected the collaborations through a
competitive grant application process. Over coming months, the centers
will build upon existing partnerships between the respective academic
institutions and apply the funding to assess training needs, adapt
educational materials and curricula, and help accelerate the roll out of
new training courses for immunization managers.
As also noted in today's announcement, The Merck Company Foundation will
renew its funding for existing Merck Vaccine Network – Africa centers
in:
Kenya, a collaboration between Indiana University School of Medicine
(Indianapolis, Indiana, U.S.A.) and Moi University School of Medicine
(Eldoret, Kenya); and
Mali, a collaboration between the University of Maryland School of
Medicine Center for Vaccine Development (Baltimore, Maryland, U.S.A.) and
Centre pour le Développement des Vaccins-Mali (Bamako, Mali).
Each existing center will receive an annually renewable grant of $200,000,
up to a maximum of $600,000 over three years.
Over the past four years, Merck Vaccine Network – Africa partners in
Kenya and Mali have worked to develop training programs based on
comprehensive in-country assessments of immunization management needs.
Designed for mid- to high-level immunization program managers, courses
have included management training on storing and handling vaccines safely,
forecasting community needs to ensure an adequate vaccine supply, planning
and conducting disease surveillance activities, and providing supportive
supervision to lower-level staff. Training materials are based on
educational source materials developed by the World Health Organization
and other GAVI partners. To date, more than 350 health professionals have
completed MVN-A training in Kenya and Mali and returned to their home
medical facilities to share their expertise and knowledge with colleagues
at the front line.
"We know that a significant cause of low immunization coverage in Africa
is the lack of trained health care workers," said Professor Abdel Kader
Traore of the Malian Ministry of Health. "The Merck Vaccine Network –
Africa is helping the Republic of Mali and its people address this
critical issue by building a skilled cadre of immunization managers. This
partnership is a testament to how the public and private sectors can come
together to help strengthen health care capacity and ensure the health of
our nation's children."
Today's renewed funding will allow the centers to expand training to
additional health workers within each country and explore new, innovative
training methods to address emerging immunization management needs.
"Today's announcement gives increased hope for bridging some of the health
care inequalities that exist between developed and developing countries,"
said Stephanie James, Ph.D., Advisor to the Merck Vaccine Network –
Africa. "Over time, Merck Vaccine Network – Africa training centers, in
combination with other local and global initiatives, will help strengthen
health care capacity in developing countries, allowing children greater
access to life-saving vaccines."
Merck Vaccine Network – Africa: Part of Merck & Co., Inc.'s
Commitment to the Developing World
The Merck Vaccine Network – Africa is an important part of Merck & Co.,
Inc.'s overall commitment to improving access to medicines and vaccines in
the developing world, which is based on a three-pronged approach:
Discovering, developing and delivering breakthrough medicines and
vaccines that address major burdens of illness globally.
Developing long-term strategies that ensure access to our products.
This includes a differential pricing policy through which we provide our
vaccines and anti-retroviral (ARV) medicines at dramatically lower prices
- at which Merck does not profit – to people living in the world's
poorest countries and those hardest hit by disease.
Promoting and participating in partnerships with governments,
multilateral organizations, community-based organizations, other
corporations and non-governmental organizations to help build health care
capacity through disease education, health professional training and
service initiatives. We also work through innovative partnerships to help
assess disease burden, evaluate effective models for vaccine introduction,
and pursue programs to demonstrate feasibility of immunization programs
and the impact of vaccine introduction.
Other examples of Merck initiatives that address health issues in Africa
include:
The Merck MECTIZAN® Donation Program, established by Merck & Co.,
Inc., in 1987 to combat the tropical disease river blindness, and, which
today, is the longest-running medicine donation commitment in history.
The African Comprehensive HIV/AIDS Partnerships, a public-private
partnership between the Government of Botswana, the Bill & Melinda Gates
Foundation and Merck & Co. Inc./ The Merck Company Foundation to enhance
and support Botswana’s national HIV/AIDS program through a comprehensive
approach to prevention, treatment, care and support.
The Merck partnership established in 2005 with the PATH Rotavirus
Vaccine Program, to conduct clinical trials of Merck & Co., Inc.'s vaccine
for rotavirus in least developed countries to help accelerate the
availability of the vaccine in the most impoverished nations. In Africa,
trials are underway in Ghana, Kenya and Mali.
The GARDASIL(R) Access Program, an initiative established in 2007 by
Merck & Co., Inc., to donate at least 3 million doses of its cervical
cancer vaccine to support vaccination programs in lowest income nations.
Clinical trials of GARDASIL in targeted populations are also ongoing in
Africa.
For more information on these and other programs, visit www.merck.com
About The Merck Company Foundation
2007 marks the 50th anniversary of The Merck Company Foundation, a
U.S.-based, private charitable foundation. Established in 1957 by the
global research-driven pharmaceutical company Merck & Co., Inc., the
Foundation is funded entirely by Merck and is its chief source of funding
support to qualified non-profit, charitable organizations. The mission of
the Foundation is to support organizations and innovative programs that:
expand access to medicines, vaccines and quality health care; build
capacity in the biomedical and health sciences; promote environments that
encourage innovation, economic growth and development in a fair and
ethical context; and support communities where Merck has a major presence.
For more information, visit www.merckcompanyfoundation.org.
About Merck
Merck & Co., Inc. located in Whitehouse Station, N.J., U.S.A., also known
as Merck Sharp & Dohme (MSD) in most countries outside the U.S., is a
global research-driven pharmaceutical company dedicated to putting
patients first. Established in 1891, Merck currently discovers, develops,
manufactures and markets vaccines and medicines in over 20 therapeutic
categories. The Company also devotes extensive efforts to increase access
to medicines through far-reaching programs that not only donate Merck
medicines but help deliver them to the people who need them. Merck also
publishes unbiased health information as a not-for-profit service. For
more information, visit www.merck.com.
|
|